idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
Li-Fraumeni syndrome: Study provides new approaches for personalised care for those affected
Li-Fraumeni syndrome is a rare hereditary disease that significantly increases the risk of developing cancer. Almost all affected individuals receive a cancer diagnosis at least once in their lifetime. A new study suggests that the immune system is partly responsible for why cancer occurs at very different ages and in different forms. This opens up new perspectives for personalised treatment approaches in the future. The international team published their findings in the Lancet journal.
Cross-border research may explain variable cancer risk
Li-Fraumeni syndrome is caused by inherited changes in a gene called TP53, which normally helps protect the body from cancer," explains Professor Christian Kratz, Director of the Department of Paediatric Haematology and Oncology at Hannover Medical School (MHH) and co-initiator of the study. "Those affected have a high lifetime risk of developing cancer. In addition, individual cancer risk can vary significantly even within the same family." In the cross-national study, led by representatives Université Grenoble Alpes/ Inserm U1209 IAB, the Université de Rouen Normandie/ Inserm U1245 CBG in France and the MHH, the researchers wanted to gain a better understanding of the causes of this variability.
Immune cells can detect genetic changes
The study investigated whether the body's own immune system could play a role in the development of cancer. "We focused on how different changes in the TP53 gene are recognised by immune cells," explains Emilie Montellier of the Inserm. "Some altered forms of the p53 protein can produce small fragments that the immune system recognises as abnormal, which is associated with a reduced risk of cancer."
By analysing genetic and clinical data from thousands of people with Li-Fraumeni syndrome, the researchers identified a clear pattern: individuals who carried variants in the TP53 gene that were more likely to be recognised by the immune system tended to develop cancer later in life. They were also less likely to develop some of the cancers most commonly associated with Li-Fraumeni syndrome, such as bone and soft tissue sarcomas.
Reduced overall risk of cancer
The findings suggest that the immune system influences how inherited cancer risk develops over the course of a person's life. Although immune recognition does not prevent cancer from developing in people with Li-Fraumeni syndrome, it may help reduce overall risk by delaying the onset of cancer or changing the type of cancers that occur.
"Our work has no immediate impact on medical care, but it opens up new possibilities for personalised approaches in the future," explains Gaëlle Bougeard of the University of Rouen Normandy. "Information about a person's specific TP53 variant and immune system background could help doctors better tailor cancer monitoring and prevention strategies in the future."
"More generally, these results show how interactions between genetic variations and the immune system can influence cancer risk – not only in Li-Fraumeni syndrome, but possibly also in other hereditary cancers," adds Professor Kratz. Professor Kratz receives support for his research from the German Childhood Cancer Foundation.
An obituary for Professor Pierre Hainaut, who played a key role in advancing the study and tragically passed away after submitting the manuscript, can be found at https://doi.org/10.1093/jnci/djaf257.
SERVICE
Further information on Li-Fraumeni syndrome can be found at http://www.krebs-praedisposition.de
For further information, please contact Professor Christian Kratz, kratz.christian@mh-hannover.de.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00509-2/fullte...
The researchers from France and Germany (from left): Emilie Montellier from the Inserm, MHH Professo ...
Copyright: Elotine Photo, Christian Wyrwa/wyrwa fotografie, Gaëlle Bougeard, Thomas Bianchin.
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
